Please login to the form below
Memorial Sloan Kettering
This page shows the latest Memorial Sloan Kettering news and features for those working in and with pharma, biotech and healthcare.
Sanofi signs $1bn licence agreement for Eureka’s novel multiple myeloma drug
Multiple myeloma is the second most common blood cancer. Sanofi has announced a new licence agreement, potentially worth up to $1bn, with US biotech company Eureka Therapeutics and the Memorial Sloan ... Kettering Cancer Center (MSK) for a novel multiple
Latest news
-
FDA begins speedy review of BMS’ CAR-T liso-cel
The lawsuit argued that Gilead subsidiary Kite Therapeutics infringed on a patent licensed by BMS’ Juno Therapeutics from Sloan Kettering and Memorial Sloan Kettering Cancer Centre for exclusive rights to its ... BMS alleged that Kite scientists copied
-
US start-up EQRx promises approach that will slash drug prices
EQRx is co-founded by Peter Bach, director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center whose academic interests focus on pricing as well as
-
Gilead owes BMS millions after losing Yescarta patent infringement trial
Memorial Sloan Kettering Cancer Center for the exclusive rights to the technology. ... We remain steadfast in our opinion that Sloan Kettering's patent is not infringed and is invalid," it said.
-
Rival Novartis, Merck drugs square up on rare lung cancer at ASCO
Tepotinib also seemed to work in patients with brain metastases who “benefitted equally” from treatment, according to lead investigator Paul Paik of Memorial Sloan Kettering Cancer Centre in the US.
-
AZ’s Sean Bohen to exit after business overhaul; report
Last week’s business reshuffle also saw Memorial Sloan Kettering Cancer Center physician José Baselga brought in to head the company’s cancer R&D unit – a somewhat controversial choice given
FDA begins speedy review of BMS’ CAR-T liso-cel
US start-up EQRx promises approach that will slash drug prices
Gilead owes BMS millions after losing Yescarta patent infringement trial
Rival Novartis, Merck drugs square up on rare lung cancer at ASCO
AZ’s Sean Bohen to exit after business overhaul; report
More from news
Approximately 1 fully matching, plus 30 partially matching documents found.
Latest Intelligence
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
Strategies for sourcing external innovation include collaborations with universities and leading academic research centers based on their research focus (eg, oncology companies partnering with Memorial Sloan Kettering Cancer Center) and geographic
-
Encouraging signs in biomarker R&D
He also cited an FDA-approved TMB test developed by Foundation Medicine and Memorial Sloan Kettering Cancer Center as an example.
-
Deal Watch September 2016
No other financial details were disclosed. Fate Therapeutics entered a three year arrangement with Memorial Sloan Kettering Cancer Center to use engineered pluripotent cell lines to develop T cell product candidates.
Sourcing R&D innovation: why pharma companies need to evolve their business models
Encouraging signs in biomarker R&D
Deal Watch September 2016
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
ICR appoints Kristian Helin as its new chief executive
Helin will join ICR in September from the Memorial Sloan Kettering Cancer Center in the US. ... Helin will join the ICR from Memorial Sloan Kettering Cancer Center in the US, where he currently serves as chair of the cell biology programme and director
-
Lilly appoints Maura Dickler as VP of late phase oncology development
She will join the pharma firm from the Memorial Sloan Kettering Cancer Center. ... She will move to the pharmaceutical company from the prestigious Memorial Sloan Kettering Cancer Center, where she currently serves as associate member, Breast Medicine
-
José Baselga joins BMS’ board of directors
Dr Baselga is currently the physician in chief at Memorial Sloan Kettering Cancer Center, where he is responsible for the management of patients care, enhancing and expanding programmes in clinical and
-
OncoMed’s CMO steps down
Prior to this, Dr Dupont was director of early and late stage development at Genentech, and served as a researcher in tumour immunology at the Memorial Sloan Kettering Cancer Center.
ICR appoints Kristian Helin as its new chief executive
Lilly appoints Maura Dickler as VP of late phase oncology development
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Getting personal with wearable tech
In July 2016, a prestigious US cancer centre, The Memorial Sloan Kettering Cancer Center (MSK), announced their plans to evaluate wearables and other mobile technology to assess cancer patients' quality of
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- US demand for COVID-19 antibody treatments rising fast
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- David Hunt launches independent agency The Considered
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- Live Webinar: Artificial Intelligence for Improving Patient Outcomes & Operational Efficiency
- CHANGING FACES: UNDERSTANDING THE KEY CUSTOMER CONTACT POINTS WITHIN THE ICS LANDSCAPE
- FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer
- AstraZeneca chooses Ireland for $360m manufacturing site
- Building the perfect behaviour-change buffet
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- David Hunt launches independent agency The Considered
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- The transatlantic opioid crisis
- WHO to test three more potential COVID-19 treatments
- EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy
PMHub
Cegedim Health Data
Cegedim Health Data provides Real World Data and Evidence services to enable advancements in patient outcomes. With a data history...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
